Par snaps up Indian generic firm Edict
This article was originally published in Scrip
Executive Summary
M&A activity, albeit not big ticket deal-making, appears to on the upswing in India. Par Pharmaceutical has snapped up the privately owned Indian generic firm, Edict Pharmaceuticals, for up to $37.6 million in cash, in addition to repayment of certain debt of Edict.